Bayer: Nubeqa reduces risk of death from prostate cancer

(CercleFinance.com) - Bayer's Nubeqa has been shown to reduce the risk of death in men with prostate cancer, the German chemicals and pharmaceuticals said on Thursday.


This androgen receptor inhibitor, plus androgen deprivation therapy, reduced the risk of death by 31% compared to placebo in men with non-metastatic castration-resistant prostate cancer (nmCRPC), the group said.

This data from a final analysis of a Phase III trial will be presented at the American Society of Clinical Oncology (ASCO) virtual meeting to be held on 29-31 May.

Copyright (c) 2020 CercleFinance.com. All rights reserved.